FemZone trial: A randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Fasching, Peter A ^a   Jud, Sebastian M ^a   Hauschild, Maik ^b   Kümmel, Sherko ^c   Schütte, Martin ^c   Warm, Matthias ^d,e   Hanf, Volker ^f   Grab, Dieter ^g   Krocker, Jutta ^h   Stickeler, Elmar ⁱ   Kreienberg, Rolf ^j   Müller, Thomas ^k   Kühn, Thorsten ^l   Wolf, Christopher ^m   Kahlert, Steffen ^o   Paepke, Stefan ⁿ   Berghorn, Michael ^p   Muth, Mathias ^q   Baier, Monika ^q   Wackwitz, Birgit ^q   Schulz Wendtland, Rüdiger ^r   Beckmann, Matthias W ^a   Lux, Michael P ^a   more..

^a Friedrich Alexander University Erlangen Nuremberg   (Germany)

^b Departement of Gynecology and Obstetrics   (Switzerland)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Kliniken der Stadt Koln   (Germany)

^f KLINIKUM FÜRTH   (Germany)

^g Klinikum Harlaching   (Germany)

^h MARTIN LUTHER KRANKENHAUS   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j UNIVERSITY HOSPITAL ULM   (Germany)

^k Frauenklinik   (Germany)

^l KLINIKUM ESSLINGEN   (Germany)

^m Medizinisches Zentrum Ulm   (Germany)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^p ALLGEMEINES KRANKENHAUS CELLE   (Germany)

^q NOVARTIS PHARMA GMBH   (Germany)

^r UNIVERSITY HOSPITAL ERLANGEN   (Germany)

more..

Author keywords

Aromatase inhibitors; Bisphosphonates; Breast cancer; Letrozole; Neoadjuvant treatment; Zoledronic acid

Indexed keywords

LETROZOLE; ZOLEDRONIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FRACTURE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HUMAN TISSUE; INFECTION; INFESTATION; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDIASTINUM DISEASE; MEDICATION COMPLIANCE; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; THORAX DISEASE; TREATMENT DURATION; TUMOR VOLUME; VERTIGO; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 84896710025     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-66     Document Type: Article

References (32)

1. Kolberg HC, Luftner D, Lux MP, Maass N, Schutz F, Fasching PA, Fehm T, Janni W, Kummel S. Breast Cancer 2012-New Aspects. Geburtsh Frauenheilk 2012, 72(7):602-615.
2. Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Canc Res Off J Am Assoc Canc Res 2006, 12(20 Pt 2):6258s-6263s.
3. Ural AU, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Med Oncol 2008, 25(3):350-355. 10.1007/s12032-008-9044-4, 18202925.
4. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, et al. Breast-cancer adjuvant therapy with zoledronic acid. New Engl J Med 2011, 365(15):1396-1405. 10.1056/NEJMoa1105195, 21995387.
5. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 2009, 360(7):679-691. 10.1056/NEJMoa0806285, 19213681.
6. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol Off J Euro Soc Med Oncol ESMO 2010, 21(11):2188-2194.
7. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12(7):631-641. 10.1016/S1470-2045(11)70122-X, 21641868.
8. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Canc Res Off J Am Assoc Can Res 2002, 8(5):1080-1084.
9. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Canc Res Off J Am Assoc Canc Res 2003, 9(8):2893-2897.
10. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Canc Res Off J Am Ass Canc Res 2007, 13(15 Pt 1):4482-4486.
11. Monkkonen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsalainen J, Monkkonen J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006, 147(4):437-445. 10.1038/sj.bjp.0706628, 1616989, 16402039.
12. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003, 170(1):246-252. 10.1097/01.ju.0000070685.34760.5f, 12796698.
13. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Canc 2003, 88(10):1631-1640.
14. Paepke S, Blohmer JU, Warm M, Ohlinger R, Kiechle M. Zoledronic Acid in Adjuvant Therapy of Receptor Negative Early Breast Cancer - Rationale and First Experience in Individual Therapy Strategy. Geburtsh Frauenheilk 2011, 71(2):135-139.
15. Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR, Fanale D, Margarese N, Santini D, Bazan V, et al. Analysis of molecular mechanisms and anti-tumoral effects of zoledronic acid in breast cancer cells. J Cell Mol Med 2012, 16(9):2186-2195. 10.1111/j.1582-4934.2012.01527.x, 22260151.
16. Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol Off J Euro Soc Med Oncol ESMO 2012, 23(3):597-604.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
18. Heusinger K, Lohberg C, Lux MP, Papadopoulos T, Imhoff K, Schulz-Wendtland R, Beckmann MW, Fasching PA. Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself*. Breast Canc Res Treat 2005, 94(1):17-23.
19. Loehberg CR, Lux MP, Ackermann S, Poehls UG, Bani MR, Schulz-Wendtland R, Papadopoulos T, Schmucker M, Beckmann MW, Fasching PA. Neoadjuvant chemotherapy in breast cancer: which diagnostic procedures can be used?. Anticancer Res 2005, 25(3c):2519-2525.
20. Meier-Meitinger M, Haberle L, Fasching PA, Bani MR, Heusinger K, Wachter D, Beckmann MW, Uder M, Schulz-Wendtland R, Adamietz B. Assessment of breast cancer tumour size using six different methods. Eur Radiol 2011, 21(6):1180-1187. 10.1007/s00330-010-2016-z, 21191794.
21. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006, 106(10):2095-2103. 10.1002/cncr.21872, 16598749.
22. Smith IE. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 2003, 86(3-5):289-293.
23. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 2005, 23(22):5108-5116.
24. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol Off J Eur Soc Med Oncol ESMO 2001, 12(11):1527-1532.
25. Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Canc 2010, 103(6):759-764.
26. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z103. J Clin Oncol Off J Am Soc Clin Oncol 2011, 29(17):2342-2349.
27. Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 2009, 198(4):520-525. 10.1016/j.amjsurg.2009.06.004, 3924770, 19800460.
28. Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: more questions than answers. J Clin Oncol Off J Am Soc Clin Oncol 2005, 23(22):4842-4844.
29. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Canc 2010, 102(7):1099-1105.
30. Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 2012, 118(2):326-332. 10.1002/cncr.26144, 3158806, 21590688.
31. Charehbili A, van de Ven S, Liefers GJ, Smit VTHBM, Putter H, Heijns JB, van Warmerdam L, Kessels L, Dercksen W, Pepels MJ, et al. NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)-A Dutch Breast Cancer Trialists' Group (BOOG) study. J Clin Oncol 2013, 31. http://meetinglibrary.asco.org/content/114337-132.
32. Horiguchi J, Hasegawa Y, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, et al. A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. J Clin Oncol 2013, 31. http://meetinglibrary.asco.org/content/110978-132.